IGF-1 LR3 1mg

IGF-1 LR3 (insulin-like growth factor-1 long arginine 3) is a synthetic, modified construct of insulin-like growth factor-1. Because IGF-1 LR3 does not bind to IGF-1 binding proteins very well, it remains active up to 120 times longer than standard IGF-1. This results in improved half-life for the peptide and thus increased activity. IGF-1 LR3 enhances cell division and growth, boosts fat metabolism, and increases muscle repair and hypertrophy by inhibiting myostatin. Recent research suggests that IGF-1 LR3 may also be useful in improving lactation among mothers with young offspring.

Properties

• • • Chemical Formula: C400H625N111O115S9
    • Molecular Mass: 9117.60
    • Synonyms: Long R3-IGF-1, M9L22Y19H9, 143045-27-6, Long-(arg3)insulin-like growth factor-i
    • CAS Number: 143045-27-6
    • PubChem: 381123731
    • Total Amount of the Active Ingredient: 1 mg (1 vial)
    • Shelf Life: 36 months

Benefit

• CELL DIVISION
  Like IGF-1, research suggests that Receptor Grade IGF-1 LR3 may act as a stimulus for cell division and proliferation, primarily affecting connective tissues of the muscle and bone and cell division in the liver, kidney, skin, lung, nerve, and blood tissues. IGF-1 is best considered to be a maturation hormone because of its apparent influence in cell proliferation, differentiation, and maturation, helping them to carry out their specialized functions. The longer life span of Receptor Grade IGF-1 LR3 in the blood makes it a more potent molecule as compared to IGF-1. A single dose of Receptor Grade IGF-1 LR3 appears to provide about three times as much cellular activation compared to a similar dose of IGF-1. Researchers report that “The response with LR3IGF-I was particularly striking because this peptide binds 3-fold less well than IGF-I to the type 1 IGF receptor.“ It is important to remember that IGF-1 LR3 peptide and every IGF-1 derivative have not been observed to mediate cellular enlargement (hypertrophy), and instead may participate in cell division and proliferation (hyperplasia). For instance, in the case of muscle, studies suggest Receptor Grade IGF-1 LR3 would not cause enlargement of muscle cells, rather simply increasing the total number of muscle cells.
• MYOSTATIN
  Myostatin (also known as growth differentiation factor 8) is a muscle protein that primarily suppresses the growth and differentiation of muscle cells. Myostatin is, thus crucial in protection from unregulated hypertrophy and proper healing post-injury. However, some situations that demand inhibition of myosin. Blocking of myosin can be helpful in conditions like Duchenne Muscular Dystrophy (DMD) or in people who suffer from loss of muscle due to prolonged immobility. In such cases, blocking the natural enzyme could help slow down muscle breakdown, maintain strength, and avoid morbidity. Studies conducted in mouse models of DMD have suggested that Receptor Grade IGF-1 LR3 and other IGF-1 derivatives may overcome the adverse effects of Myostatin to protect muscle cells and prevent apoptosis.^[3] The scientists note that “results together suggest that myostatin suppresses both basal and IGF-1-stimulated proliferation of both WAT and BAT preadipocytes, actions that are again similar to those in muscle satellite cells”. Receptor Grade IGF-1 LR3, due to its long stability, may be effective in counteracting Myostatin by activating MyoD, a muscle protein that is normally triggered by exercise (e.g., weight lifting).
• METABOLISM, DIABETES
  Researchers suggest that Receptor Grade IGF-1 LR3 indirectly boosts fat burning by associating with the IGF-1R receptor and the insulin receptor. These interactions may improve glucose uptake from the blood by muscle, nerve, and liver cells. This potential would result in an overall reduction in blood sugar levels, which then trigger adipose tissue as well as the liver to initiate catabolism of glycogen and triglycerides. Overall, this leads to a decrease in adipose tissue and net energy consumption (i.e. net catabolism). Given its role in controlling blood sugar levels, Receptor Grade IGF-1 LR3 may reduce insulin levels and the need for exogenous insulin in diabetes.  In a majority of the patients, this brings about a 10% reduction in insulin requirements to maintain the same blood sugar levels.^[4] Receptor Grade IGF-1 LR3 thus helps understand insulin regulation in patients with decreased insulin sensitivity. It also highlights possible ways to prevent type 2 diabetes.
• LONGEVITY RESEARCH
  Studies observe that Receptor Grade IGF-1 LR3 may promote tissue repair and upkeep of the body, making it a protective molecule against cellular damage and the effects of aging. Research in cows and pigs indicate that Receptor Grade IGF-1 LR3 administration may overcome the effects of aging, prolong life and reduce disability. Ongoing research in mice has focused on the potential of Receptor Grade IGF-1 LR3 in preventing the progression of a wide range of conditions such as muscle atrophy, dementia, and kidney disease
• GLUCOCORTICOID SIGNALING
  Glucocorticoids, produced essentially from the adrenal glands, also act as important clinical medications which help to control pain and decrease inflammation in autoimmune diseases, cancer, and neurological injuries, to name a few. However, glucocorticoids have numerous undesirable side effects, such as muscle wasting, fat gain, and deterioration of bone density. Thus, Receptor Grade IGF-1 LR3 is being explored as an option to reduce the side effects of glucocorticoids and thereby mediate a more effective therapy. Studies have shown minimal to moderate side effects, low oral bioavailability, and excellent subcutaneous bioavailability in mice.^[6] Per kg dosage in mice does not scale up to the dosage which can be required for humans.

Product Quality

Lab tests are occasionally published on the website. You can have the product you bought from us tested at any HPLC licensed testing facility and if the results are negative, we will refund the following:

• • Cost of HPLC test
  • Total amount of the order + shipping fee

Dosage

Dosage suggestion from studies agree to inject 20-50 mcg SQ/IM daily for a max of 6-7 weeks. Dosing from 50 – 80 mcg can also be used with caution and under the supervision of a physician. Muscle pain can occur with higher dosing.

Desensitization can and does occur around 6 weeks after initial time of use. It is recommended to take 20-40 days off prior to starting another course of IGF1/LR3 again .

Some physicians suggest consuming protein with a blend of simple & complex carbohydrates 15-20 minutes prior to administering IGF-1/ LR3. Other recommend taking the medication before bed because that is when your body naturally replenishes its own growth hormone.